NCT02096042 Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML) Status TERMINATED Phase PHASE1/PHASE2
NCT02095951 Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection Status COMPLETED Phase PHASE4
NCT02089230 MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy Status TERMINATED Phase PHASE1/PHASE2
NCT02065154 Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis Status COMPLETED Phase PHASE2
NCT02053545 Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion Status WITHDRAWN Phase PHASE1/PHASE2
NCT02043184 Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR Status COMPLETED Phase NA
NCT02028039 IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) Status WITHDRAWN Phase PHASE2
NCT02010645 Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS) Status TERMINATED Phase PHASE2
NCT02007863 Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia Status COMPLETED Phase NA
NCT01983761 Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation Status UNKNOWN Phase PHASE1/PHASE2
NCT01971476 Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known Status COMPLETED Phase PHASE1
NCT01932710 A Feasibility Study of Prophylactic White Blood Cell Transfusions Status COMPLETED Phase PHASE2
NCT01931644 At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions Status COMPLETED Phase N/A
NCT01929720 Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors Status COMPLETED Phase NA
NCT01920737 A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT01919619 Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies Status COMPLETED Phase PHASE2
NCT01915992 Natural Killer Cells Functions, Tumoral Escape to Immune System and Regulation of Natural Cytotoxixity Receptors in Haematological Malignancies Status UNKNOWN Phase NA
NCT01904175 Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant Status COMPLETED Phase N/A